From penetrating solid tumors to new success rates for de novo design, the next wave of antibody therapies aims to transform the clinic.
On a 2.0 terminal benchmark, OpenAI’s model scores about 10% higher, guiding users toward stronger results on long, complex ...
What's CODE SWITCH? It's the fearless conversations about race that you've been waiting for. Hosted by journalists of color, our podcast tackles the subject of race with empathy and humor. We explore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results